Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNCT in Glioblastoma and Intracranial Melanoma
NCT00039572Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2002
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of boronophenylalanine + fructose in glioblastoma multiforme (GBM) and melanoma, sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Time course, uniformity, and severity of acute and chronic normal tissue reactions at 2 years and Maximum Tolerated Dose. Started May 2002; status: completed.
02
Drugs
boronophenylalanine + fructose
03
Conditions
glioblastoma multiforme (GBM)melanoma
Beyond the preview
Go deeper on NCT00039572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039572.